The evanescence and persistence of RBC alloantibodies in blood donors.
Journal
Transfusion
ISSN: 1537-2995
Titre abrégé: Transfusion
Pays: United States
ID NLM: 0417360
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
17
11
2019
revised:
30
01
2020
accepted:
30
01
2020
pubmed:
16
2
2020
medline:
9
9
2020
entrez:
16
2
2020
Statut:
ppublish
Résumé
Blood donors represent a healthy population, whose red blood cell (RBC) alloantibody persistence or evanescence kinetics may differ from those of immunocompromised patients. A better understanding of the biologic factors impacting antibody persistence is warranted, as the presence of alloantibodies may impact donor health and the fate of the donated blood product. Donor/donation data collected from four US blood centers from 2012 to 2016 as part of the Recipient Epidemiology and Donor Evaluation Study-III (REDS-III) were analyzed. Clinically significant antibodies from blood donors with more than one donation who underwent at least one follow-up antibody screen after the initial antibody identification were included. Of 632,378 blood donors, 481 (128 males and 353 females) fit inclusion criteria. Antibody screens detected 562 alloantibodies, with 368 of 562 (65%) of antibodies being persistently detected and with 194 of 562 (35%) becoming evanescent. Factors associated with antibody persistence included antibody specificity, detection at the first donation, reported history of transfusion, and detection of multiple antibodies concurrently. Anti-D, C, and Fy These data provide insight into variables impacting the duration of antibody detection, and they may also influence blood donor center policies regarding donor recruitment/acceptance.
Sections du résumé
BACKGROUND
Blood donors represent a healthy population, whose red blood cell (RBC) alloantibody persistence or evanescence kinetics may differ from those of immunocompromised patients. A better understanding of the biologic factors impacting antibody persistence is warranted, as the presence of alloantibodies may impact donor health and the fate of the donated blood product.
METHODS
Donor/donation data collected from four US blood centers from 2012 to 2016 as part of the Recipient Epidemiology and Donor Evaluation Study-III (REDS-III) were analyzed. Clinically significant antibodies from blood donors with more than one donation who underwent at least one follow-up antibody screen after the initial antibody identification were included. Of 632,378 blood donors, 481 (128 males and 353 females) fit inclusion criteria.
RESULTS
Antibody screens detected 562 alloantibodies, with 368 of 562 (65%) of antibodies being persistently detected and with 194 of 562 (35%) becoming evanescent. Factors associated with antibody persistence included antibody specificity, detection at the first donation, reported history of transfusion, and detection of multiple antibodies concurrently. Anti-D, C, and Fy
CONCLUSIONS
These data provide insight into variables impacting the duration of antibody detection, and they may also influence blood donor center policies regarding donor recruitment/acceptance.
Substances chimiques
Isoantibodies
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
831-839Informations de copyright
© 2020 AABB.
Références
Hendrickson JE, Tormey CA, Shaz BH. Red blood cell alloimmunization mitigation strategies. Transfus Med Rev 2014;28:137-44.
Tormey CA, Stack G. The persistence and evanescence of blood group alloantibodies in men. Transfusion 2009;49:505-12.
US Department of Health and Human Services. Fatalities reported to the FDA following blood collection [Internet]. Rockville (MD): FDA. [cited 2019 Nov 17]. Available from: https://www.fda.gov/vaccines-blood-biologics/report-problem-center-biologics-evaluation-research/transfusiondonation-fatalities.
Siddon AJ, Kenney BC, Hendrickson JE, et al. Delayed haemolytic and serologic transfusion reactions: pathophysiology, treatment and prevention. Curr Opin Hematol 2018;25:459-67.
Stack G, Tormey CA. Estimating the immunogenicity of blood group antigens: a modified calculation that corrects for transfusion exposures. Br J Haematol 2016;175:154-60.
Tormey CA, Stack G. Immunogenicity of blood group antigens: a mathematical model corrected for antibody evanescence with exclusion of naturally occurring and pregnancy-related antibodies. Blood 2009;114:4279-82.
Williams LA 3rd, Lorenz RG, Tahir A, et al. High percentage of evanescent red cell antibodies in patients with sickle cell disease highlights need for a national antibody database. South Med J 2016;109:588-91.
Schonewille H, Haak HL, van Zijl AM. RBC antibody persistence. Transfusion 2000;40:1127-31.
Stack G, Tormey CA. Detection rate of blood group alloimmunization based on real-world testing practices and kinetics of antibody induction and evanescence. Transfusion 2016;56:2662-7.
Verduin EP, Brand A, van de Watering LM, et al. Factors associated with persistence of red blood cell antibodies in woman after pregnancies complicated by fetal alloimmune haemolytic disease treated with intrauterine transfusions. Br J Haematol 2015;168:443-51.
AABB Standards Committee. Standards for blood banks and transfusion services. 31st ed. Bethesda (MD): AABB Press; 2018.
Karafin MS, Tan S, Tormey CA, et al. Prevalence and risk factors for RBC alloantibodies in blood donors in the Recipient Epidemiology and Donor Evaluation Study-III (REDS-III). Transfusion 2019;59:217-25.
Karafin MS, Westlake M, Hauser RG, et al. Risk factors for red blood cell alloimmunization in the Recipient Epidemiology and Donor Evaluation Study (REDS-III) database. Br J Haematol 2018;181:672-81.
Wei L-J, Lin DY, Weissfeld L. Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. J Am Stat Assoc 1989;84:1065-73.
Myhre BA, Greenwalt TJ, Gajewski M. Incidence of irregular antibodies occurring in healthy donor sera. Transfusion 1965;15:350-4.
Plumbley JA, Shelton JB Jr, Bowlus IN, et al. The incidence of unexpected antibodies in blood products collected at a military donor center. Mil Med 1999;164:705-6.
Garcia MA, Bautista L, Palomino F. Should blood donors be routinely screened for irregular antibodies? Immunohematology 2012;28:60-6.
Tormey CA, Stack G. The characterization and classification of concurrent blood group antibodies. Transfusion 2009;49:2709-18.
Noiret L, Slater A, Higgins JM. Determinants of red blood cell alloantibody detection duration: analysis of multiply alloimmunized patients supports peritransfusion factors. Transfusion 2017;57:1930-7.
Patel SR, Bennett A, Girard-Pierce K, et al. Recipient priming to one RBC alloantigen directly enhances subsequent alloimmunization in mice. Blood Adv 2018;2:105-15.
Triulzi DJ, Kleinman S, Kakaiya RM, et al. The effect of previous pregnancy and transfusion on HLA alloimmunization in blood donors: implications for a transfusion-related acute lung injury risk reduction strategy. Transfusion 2009;49:1825-35.